Detalhe da pesquisa
1.
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Ann Oncol
; 34(4): 389-396, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36709039
2.
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Ann Oncol
; 33(4): 416-425, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35026412
3.
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.
Ann Oncol
; 33(9): 909-915, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35654248
4.
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Ann Oncol
; 33(4): 434-444, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35066105
5.
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Ann Oncol
; 33(4): 406-415, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35026411
6.
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Ann Oncol
; 33(10): 1041-1051, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35850444
7.
Increasing global accessibility to high-level treatments for cervical cancers.
Gynecol Oncol
; 164(1): 231-241, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34716024
8.
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Ann Oncol
; 32(6): 698-709, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33737119
9.
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
Ann Oncol
; 32(11): 1381-1390, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34416362
10.
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.
Ann Oncol
; 32(12): 1597-1607, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34487855
11.
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.
Ann Oncol
; 31(5): 626-633, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32205017
12.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Ann Oncol
; 31(3): 377-386, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32067679
13.
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Invest New Drugs
; 38(2): 402-409, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30953269
14.
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
Ann Oncol
; 29(suppl_1): i28-i37, 2018 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29462256
15.
Epigenetic modifiers as new immunomodulatory therapies in solid tumours.
Ann Oncol
; 29(4): 812-824, 2018 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29432557
16.
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
Ann Oncol
; 29(9): 1964-1971, 2018 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30010763
17.
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
Ann Oncol
; 29(9): 1911-1917, 2018 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30060061
18.
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.
Ann Oncol
; 29(1): 30-35, 2018 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29140430
19.
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Ann Oncol
; 29(3): 700-706, 2018 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29216356
20.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Ann Oncol
; 29(5): 1304-1311, 2018 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29788155